Amplifica starting clinical trials for new hair loss drug. SCUBE3 protein discovered, stimulates hair growth, could be alternative to Minoxidil and Finasteride.
The user is using a combination of RU58841, Stemoxydine, RevivHair Serum, hair growth oil, topical Minoxidil, Alfatradiol, oral Minoxidil, and Finasteride to treat hair loss. They report no side effects from oral Minoxidil and Finasteride after 7 months of use.
Hair loss progress in 4.5 months using dutasteride 3x/week, topical minoxidil 1-2x daily, and microneedling 2x/month. Users praised the significant improvement.
MaximusDurkimus shares experience with 0.25mg Finasteride, Minoxidil-induced lupus, and less than 10mg RU58841 for hair loss. Plans to try 0.025% topical Finasteride with 5% Stemoxydine and possibly Tretinoin, Fluridil, or CB-03-01 in the future.
The conversation discusses using topical dutasteride with a dermapen for hair loss treatment. The user is deciding between liposomal and mesosomal formulations for this purpose.
Two Chinese suppliers provided legitimate RU58841, confirmed through a free drug testing service. The vendors were Shaanxi Greenyo Biotech and Lyphar, found on Made-in-China.
User added RU and pyrilutamide for hair growth and noticed more baby hairs. Others suggest sticking with fin and min, while some discuss the user's self-image and hair loss severity.
A user's 12 month update on treatment for hair loss, which include oral dutasteride and minoxidil, topical RU88541 and minoxidil, microneedling with hyaluronic acid and FinDuta, experiencing no side effects, positive results and inspiring other users.
Choosing between two hair loss treatments, with a preference for a higher concentration of RU58841 and 5% minoxidil, avoiding oils like castor and argan that may hinder absorption.
The user is considering starting Minoxidil and is looking for a topical solution to combine with it. They are confused about which product to prioritize among options like RU58841, Pyrilutamide, FinaTopic, and DutaTopic.
PP405 is a new hair loss treatment showing early promise with a 20% hair density increase, but skepticism exists due to past failures of similar treatments like Pyrilutamide, RU58841, and Bimatoprost. Users debate its potential effectiveness, with some hopeful due to Google's involvement, while others urge caution without more evidence.
A user is seeing good results with RU58841 for hair loss, noting reduced shedding and thicker hair. They plan to use pumpkin seed oil as a solvent to avoid water content, which they believe reduces the effectiveness of anti-androgens.
The user has been using RU58841 for 6 months without noticeable results and is considering dropping it while continuing oral minoxidil, daily dutasteride, and topical minoxidil. Another user suggests visiting a dermatologist to check for other conditions.
RU58841, an anti-androgenic compound, showed early promise for treating alopecia but faced challenges after its patent in 1997. Despite advancing to Phase II trials, safety concerns and financial struggles led Aventis to abandon its development. Proskelia, which later merged into ProStrakan, couldn't prioritize the drug, leading to its eventual stagnation and failure to reach the market.
A user reported a 50% increase in testosterone after 18 months of taking dutasteride for hair loss. The conversation includes skepticism about the reliability of single testosterone tests and questions about estrogen levels.
Dutasteride 1.5 mg stopped shedding and reduced scalp inflammation in one month, unlike finasteride. The user also uses minoxidil but saw no results until adding dutasteride.
The conversation discusses the high prices of hair loss treatments, specifically cb-03-01 and KY19382. It also mentions the use of Minoxidil, finasteride, and RU58841.
The conversation is about trying DS Labs SOD supplements for hair loss, which contain ingredients like Genistein, B-sitosterol, and Biotin. The user is considering adding these supplements to their existing hair care routine.
The conversation is about the effectiveness and trustworthiness of Pyrilutamide hair loss treatment sold by Hairlisciously, with concerns about product purity and a request for alternative suppliers. No specific treatments were confirmed to be used by participants.
A 19-year-old is experiencing hair thinning and considering using RU58841 alongside minoxidil, which initially worked but lost effectiveness. Others advise caution, suggesting safer alternatives like topical finasteride and consulting a doctor before using unapproved treatments like RU58841.
Koshine 826 (Pyrilutamide) has mixed reviews, with some users experiencing side effects like insomnia and others seeing minimal results. Concerns about the company's transparency and lack of progress photos are noted.
The conversation is about using a hair loss treatment combining 5% RU58841 and 5% minoxidil. The user is considering trying this formula after seeing it advertised.
PTD-DBM is being explored for hair regrowth by targeting CXXC5, with clinical trials expected after pre-clinical studies. Users express anticipation and skepticism about its effectiveness.
RU58841, a hair loss treatment, is available on Amazon, but its legitimacy is questioned due to sketchy reviews and lack of lab reports. Some users report seeing results, while others experience negative side effects.
Fluridil is hard to obtain and only available in Slovakia and Czechia, with no systemic side effects but possibly limited effectiveness compared to finasteride. The original poster is using finasteride and minoxidil without success and is considering trying fluridil despite its cost.
PP405 is a potential hair loss treatment that may work by blocking signals that cause hair cells to stop growing, requiring daily application for effectiveness. It could serve as an alternative to minoxidil and finasteride, but it is not yet available on the market and may take several years to be released.
Hair loss discussion includes treatments Minoxidil, Finasteride, and RU58841. HMI 115 shows anecdotal success in Phase I trial, users seek group buy for research chemical.